BioWorld

April 3, 2003

Alvimopan Phase III Results Provide Adolor With Boost

Adolor Corp.'s stock hit a springboard, bouncing up about 31.3 percent Wednesday after the company released positive data from its first Phase III study of lead product alvimopan in the management of postoperative ileus.(BioWorld Today) Read More

Isis Cuts Staff, Curbs Programs Following Failure Of Affinitak

Alabamian Scientists Blow Cover On HIV/AIDS Virus' Quick-Change, Vaccine Defying, Escapist Artistry

Orchid Brings In $16M Through Private Sale Of Preferred Stock

MicroIslet Secures $12M For Preclinical Trials In Diabetes

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 10, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

Wuxi Apptec insists it’s ‘not a Chinese military company’

BioWorld

Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military...

Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors

BioWorld Science

Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.